Literature DB >> 30135619

ON ESTIMATION OF THE OPTIMAL TREATMENT REGIME WITH THE ADDITIVE HAZARDS MODEL.

Suhyun Kang1, Wenbin Lu1, Jiajia Zhang1.   

Abstract

We propose a doubly robust estimation method for the optimal treatment regime based on an additive hazards model with censored survival data. Specifically, we introduce a new semiparametric additive hazard model which allows flexible baseline covariate effects in the control group and incorporates marginal treatment effect and its linear interaction with covariates. In addition, we propose a time-dependent propensity score to construct an A-learning type of estimating equations. The resulting estimator is shown to be consistent and asymptotically normal when either the baseline effect model for covariates or the propensity score is correctly specified. The asymptotic variance of the estimator is consistently estimated using a simple resampling method. Simulation studies are conducted to evaluate the finite-sample performance of the estimators and an application to AIDS clinical trial data is also given to illustrate the methodology.

Entities:  

Keywords:  A-learning estimating equations; additive hazards model; doubly robust; optimal treatment regime; time-dependent propensity score

Year:  2018        PMID: 30135619      PMCID: PMC6101677          DOI: 10.5705/ss.202016.0543

Source DB:  PubMed          Journal:  Stat Sin        ISSN: 1017-0405            Impact factor:   1.261


  13 in total

1.  The additive hazards model with high-dimensional regressors.

Authors:  Torben Martinussen; Thomas H Scheike
Journal:  Lifetime Data Anal       Date:  2009-01-28       Impact factor: 1.588

2.  Efficient Estimation of Semiparametric Transformation Models for Two-Phase Cohort Studies.

Authors:  Donglin Zeng; D Y Lin
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

3.  Doubly Robust Learning for Estimating Individualized Treatment with Censored Data.

Authors:  Y Q Zhao; D Zeng; E B Laber; R Song; M Yuan; M R Kosorok
Journal:  Biometrika       Date:  2015-03-01       Impact factor: 2.445

4.  Contrasting treatment-specific survival using double-robust estimators.

Authors:  Min Zhang; Douglas E Schaubel
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

5.  Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective.

Authors:  Xiaofei Bai; Anastasios A Tsiatis; Wenbin Lu; Rui Song
Journal:  Lifetime Data Anal       Date:  2016-08-01       Impact factor: 1.588

6.  Variable selection for optimal treatment decision.

Authors:  Wenbin Lu; Hao Helen Zhang; Donglin Zeng
Journal:  Stat Methods Med Res       Date:  2011-11-23       Impact factor: 3.021

7.  Q-LEARNING WITH CENSORED DATA.

Authors:  Yair Goldberg; Michael R Kosorok
Journal:  Ann Stat       Date:  2012-02-01       Impact factor: 4.028

8.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

9.  On Estimation of Optimal Treatment Regimes For Maximizing t-Year Survival Probability.

Authors:  Runchao Jiang; Wenbin Lu; Rui Song; Marie Davidian
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2016-09-02       Impact factor: 4.488

10.  Estimating Optimal Treatment Regimes from a Classification Perspective.

Authors:  Baqun Zhang; Anastasios A Tsiatis; Marie Davidian; Min Zhang; Eric Laber
Journal:  Stat       Date:  2012-01-01
View more
  1 in total

1.  On doubly robust estimation of the hazard difference.

Authors:  Oliver Dukes; Torben Martinussen; Eric J Tchetgen Tchetgen; Stijn Vansteelandt
Journal:  Biometrics       Date:  2018-08-22       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.